Evidence map›Paper›PMID 38573438›Full record

ArticleBreast cancer (Tokyo, Japan)2024

Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.

Hiroko Nogi, Akiko Ogiya, Makoto Ishitobi, Chikako Yamauchi, Hiroki Mori, Ayaka Shimo, Kazutaka Narui, Naomi Nagura, Hirohito Seki, Shinsuke Sasada and 3 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 1 country.

Hiroko NogiDepartment of Breast and Endocrine Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minto-Ku, Tokyo, 105-8461, Japan. nogi_h@jikei.ac.jp.ORCID http://orcid.org/0000-0002-9089-1112
Akiko OgiyaDepartment of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Makoto IshitobiDepartment of Breast Surgery, Mie University School of Medicine, Mie, Japan.
Chikako YamauchiDepartment of Radiation Oncology, Shiga General Hospital, Shiga, Japan.
Hiroki MoriDepartment of Plastic and Reconstructive Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Ayaka ShimoDepartment of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan.
Kazutaka NaruiDepartment of Breast and Thyroid Surgery, Medical Center, Yokohama City University, Kanagawa, Japan.
Naomi NaguraDepartment of Breast Surgical Oncology, St Luke's International Hospital, Tokyo, Japan.
Hirohito SekiDepartment of Breast Surgery, Kyorin University School of Medicine, Tokyo, Japan.
Shinsuke SasadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Teruhisa SakuraiSakurai Breast Clinic, Wakayama, Japan.
Tadahiko ShienDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
Collaborative Study Group of Scientific Research of The Japanese Breast Cancer Society
Hiroshima University · JPJapanese Red Cross Medical Center · JPJikei University School of Medicine · JPKyorin University · JPMie University · JPOkayama University Hospital · JPShiga Medical Center · JPSt. Luke's International Hospital · JPSt. Marianna University School of Medicine · JPTokyo Medical and Dental University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn breast cancer patients receiving neoadjuvant chemotherapy (NAC), immediate breast reconstruction (IBR) as a breast cancer treatment option remains controversial. We assessed the impact of NAC on surgical and oncological outcomes of patients undergoing IBR.

methodsThis was a retrospective multicenter study of 4726 breast cancer cases undergoing IBR. The rate of postoperative complications and survival data were compared between IBR patients who received NAC and those who did not receive NAC. Propensity score matching analysis was performed to mitigate selection bias for survival.

resultsOf the total 4726 cases, 473 (10.0%) received NAC. Out of the cases with NAC, 96 (20.3%) experienced postoperative complications, while 744 cases (17.5%) without NAC had postoperative complications. NAC did not significant increase the risk of complications after IBR (Odds ratio, 0.96; 95%CI 0.74-1.25). At the median follow-up time of 76.5 months, 36 patients in the NAC group and 147 patients in the control group developed local recurrences. The 5-year local recurrence-free survival rate was 93.1% in the NAC group and 97.1% in the control group. (P < 0.001). After matching, there was no significant difference between the two groups.

conclusionIBR after NAC is a safe procedure with an acceptable postoperative complication profile.

Indexed as

Breast NeoplasmsMammaplastyMastectomyNeoadjuvant TherapyPostoperative ComplicationsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalPropensity ScoreRetrospective StudiesBreast cancerImmediate breast reconstructionLocoregional recurrenceNeoadjuvant chemotherapyPostoperative complications

Identifiers

PMID38573438
PMCPMC11045575
OpenAlexW4393933121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.